Biosimilars | Specialty

The OncLive Biosimilars condition center page is a comprehensive resource for clinical news and expert insights on currently available and investigational biosimilars for reference drugs such as trastuzumab, rituximab, bevacizumab, and more. This page features news articles, interviews in written and video format, and podcasts that focus on updates with biosimilars and ongoing research with these types of agents.

Dr. Rugo Discusses a Comparative Review of Trastuzumab Biosimilars

October 27th 2018

Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses a comparative review of trastuzumab (Herceptin) biosimilars.

Dr. Weise Discusses Challenges With Biosimilar Acceptance in Oncology

October 25th 2018

Martina Weise, MD, head of Division Licensing 2, and German CHMP member of the Federal Institute for Drugs and Medical Devices, discusses challenges with biosimilar acceptance in oncology.

Trastuzumab Biosimilars Demonstrate Equivalence Across Breast Cancer Settings

October 24th 2018

Hope S. Rugo, MD, discusses an analysis of trastuzumab biosimilars in breast cancer.

Biosimilar Excitement Rooted in Cost Reduction

October 19th 2018

Ruth O’Regan, MD, discusses the excitement with biosimilars and the potential impact they could have on the US drug market.

Dr. O'Regan on the Status of Biosimilars in Oncology

October 17th 2018

Ruth O’Regan, MD, division head, Hematology and Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, discusses the status of biosimilars in oncology.

FDA Panel Backs Rituximab Biosimilar

October 10th 2018

The FDA’s Oncologic Drugs Advisory Committee voted 16-0 recommending approval of the rituximab biosimilar CT-P10 for 3 non-Hodgkin lymphoma indications.

A Perfect Storm Brews for Biosimilar Marketing

October 3rd 2018

Pressure to reduce costs associated with biologics is one of the forces driving the rapid expansion of biosimilars, which are biological drugs that are very similar to already approved reference biologics in terms of potency, safety, and efficacy.

Approaching the Topic of Biosimilars With Patients

October 2nd 2018

Yelena Y. Janjigian, MD, discusses the reality of biosimilars entering the US market and how oncologists should approach discussing these agents with their patients.

Dr. Radich on the Potential of Biosimilars in Oncology

September 25th 2018

Jerald P. Radich, MD, clinical research division, Fred Hutchinson Cancer Research Center, discusses the potential of biosimilars in oncology.

Dr. Rule on Rituximab Biosimilar Use in the UK

September 22nd 2018

Simon Rule, MD, PhD, professor of hematology, Plymouth University Medical School, United Kingdom, discusses the use of biosimilars in the United Kingdom for the treatment of cancer.

CHMP Issues Positive Opinion on Pegfilgrastim Biosimilar

September 22nd 2018

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of their pegfilgrastim biosimilar.

Biosimilar Pipeline Continues to Offer Hope of Greater Access in Oncology

September 20th 2018

Elisavet Paplomata, MD, discusses the potential of biosimilars to help control costs and increase global access to oncology care.

Dr. Ali on Adjuvant Studies With Biosimilars in Oncology

September 19th 2018

Haythem Y. Ali, MD, senior medical oncologist, Henry Ford Hospital, discusses adjuvant studies with biosimilars in oncology.

Expert Addresses Oncology Costs, Potential Impact of Biosimilars

September 19th 2018

Lee S. Rosen, MD, FACP, discusses the benefits of bevacizumab and how biosimilars could change the field.

Brufsky Backs Biosimilars as Part of Oncology Treatment

September 17th 2018

Adam F. Brufsky, MD, PhD, discusses the differences between biosimilars and biologics, incentives for biosimilar use, and investigational agents on the horizon.

FDA Schedules ODAC Meeting for Rituximab Biosimilar

September 12th 2018

The FDA has scheduled an Oncologic Drugs Advisory Committee hearing for October 10, 2018, to discuss a biologics license application for CT-P10, a proposed biosimilar to rituximab.

Dr. Ali on Whether Biosimilars Can Replace Biologics in Oncology

August 30th 2018

Haythem Y. Ali, MD, senior medical oncologist, Henry Ford Hospital, discusses whether biosimilars can replace biologics in oncology.

Dr. Kolberg Discusses Considerations With FDA-Approved Biosimilars

August 29th 2018

Hans-Christian Kolberg, MD, head, Department of Obstetrics and Gynecology, Breast Cancer Center, and Gynecologic Cancer Center at Marienhospital Bottrop, Klinik für Gynäkologie und Geburtshilfe, Bottrop, Germany, discusses considerations for FDA-approved biosimilars.

Dr. Yardley Shares Insight on the Impact of Biosimilars

August 29th 2018

Denise Yardley, MD, senior investigator, Sarah Cannon Research Institute, shares insight on the potential impact of biosimilars in breast cancer.

Biosimilars Poised to Have Global Impact on Oncology

August 28th 2018

Sunil Verma, MD, shares insight on the benefits and unanswered questions that remain with biosimilars in oncology.